Bezafibrate/chenodeoxycholic acid - Giaconda

Drug Profile

Bezafibrate/chenodeoxycholic acid - Giaconda

Alternative Names: Hepaconda

Latest Information Update: 15 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Giaconda
  • Class Antivirals; Cholic acids; Fibric acid derivatives
  • Mechanism of Action Cholesterol 7 alpha hydroxylase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 08 Jul 2008 Suspended - Phase-II for Hepatitis C in Australia (PO) for further formulation of Hepaconda® and to secure further funding
  • 25 Jun 2007 Phase-II clinical trials in Hepatitis C treatment in Australia (PO)
  • 09 Mar 2006 Preclinical trials in Hepatitis C treatment in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top